secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001641489-24-000063
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics Q2 2024 net loss $5.2M; FDA places clinical hold on cadisegliatin T1D trial
--------------------------------------------------------------------------------

- Net loss $5.2M ($0.81/sh) vs $5.6M ($2.69/sh) in Q2 2023; cash $45.5M up from $9.4M year-end.
- FDA placed clinical hold on cadisegliatin T1D program in July; no patients dosed in pivotal trial.
- Expanded HPP737 license with Newsoara to global license contingent on $20M upfront fee.
- Cantex received Orphan Drug Designation for azeliragon in pancreatic cancer.
- R&D expenses decreased to $3.4M from $4.7M; G&A increased to $3.7M from $3.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148924000063/0001641489-24-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148924000063/vtvt-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001641489-24-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer